Entrada Therapeutics(TRDA)
BOSTON, MABiotechnology
Focus: Entrada Therapeutics is a public biotech company pioneering a proprietary platform for delivering biologics to the cytosol, addressing rare diseases across neurology, ophthalmology, and gastroenterology. The company is pre-commercial with an early-stage pipeline focused on severe rare indications.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
7-1 this month
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
Should You Work at Entrada Therapeutics?
AI assessmentBest suited for early-career researchers or clinical operations professionals seeking exposure to rare disease innovation at a lean, public-stage biotech with limited but growing momentum.
Why Work Here
- Public company with strong financial momentum: $211M revenue in FY2025 (+64% YoY) and $66M net income demonstrates path to sustainability
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$211M
Pipeline & Clinical Trials
Non-interventional
Mitochondrial Neurogastrointestinal EncephalomyopathyClinical Trials (1)
NCT04245917Natural History Study of MNGIE
N/AHelp build intelligence for Entrada Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.